Association of the Sialylation of Antibodies Specific to the HCV E2 Envelope Glycoprotein with Hepatic Fibrosis Progression and Antiviral Therapy Efficacy

Figure 1

The level of anti-E2 IgG antibodies and their sialylation (SNA reactivity) by hepatic fibrosis stage (0-4). (a) Anti-E2 IgG level. (b) SNA binding. (c) SNA binding/anti-E2 IgG level ratio. All parameters are presented in relative units (RU). The means and 95% confidence intervals are shown. values are indicated for significant differences. Stages 2 and 3 of fibrosis are combined due to the small number of patients (n =12 and 4, resp.).

(a)

(b)

(c)